# Labcorp Holdings Inc.: financial statements, quarterly

LH · NYSE · CIK 920148 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lh.md) · [Financials](/companies/lh/financials.md) · [Filings](/companies/lh/filings.md) · [Insiders](/companies/lh/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lh/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,057](/filings/0000920148-24-000118.md) | [3,033 d](/filings/0000920148-26-000111.md) | [3,177](/filings/0000920148-25-000059.md) | [3,221](/filings/0000920148-25-000081.md) | [3,282](/filings/0000920148-25-000096.md) | [3,329 d](/filings/0000920148-26-000111.md) | [3,345](/filings/0000920148-26-000139.md) | [3,527](/filings/0000920148-26-000175.md) | [3,564](/filings/0000920148-25-000096.md) | [3,516 d](/filings/0000920148-26-000111.md) | [3,538](/filings/0000920148-26-000139.md) | [3,731](/filings/0000920148-26-000175.md) |
| Cost of revenue | $m | [2,206](/filings/0000920148-24-000118.md) | [2,212 d](/filings/0000920148-26-000111.md) | [2,279](/filings/0000920148-25-000059.md) | [2,295](/filings/0000920148-25-000081.md) | [2,378](/filings/0000920148-25-000096.md) | [2,433 d](/filings/0000920148-26-000111.md) | [2,397](/filings/0000920148-26-000139.md) | [2,481](/filings/0000920148-26-000175.md) | [2,538](/filings/0000920148-25-000096.md) | [2,523 d](/filings/0000920148-26-000111.md) | [2,524](/filings/0000920148-26-000139.md) | [2,619](/filings/0000920148-26-000175.md) |
| Gross profit | $m | [851](/filings/0000920148-24-000118.md) | [821 d](/filings/0000920148-26-000111.md) | [897](/filings/0000920148-25-000059.md) | [926](/filings/0000920148-25-000081.md) | [904](/filings/0000920148-25-000096.md) | [896 d](/filings/0000920148-26-000111.md) | [948](/filings/0000920148-26-000139.md) | [1,046](/filings/0000920148-26-000175.md) | [1,025](/filings/0000920148-25-000096.md) | [993 d](/filings/0000920148-26-000111.md) | [1,014](/filings/0000920148-26-000139.md) | [1,112](/filings/0000920148-26-000175.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [526](/filings/0000920148-24-000118.md) | [533 d](/filings/0000920148-26-000111.md) | [508](/filings/0000920148-25-000059.md) | [558](/filings/0000920148-25-000081.md) | [569](/filings/0000920148-25-000096.md) | [595 d](/filings/0000920148-26-000111.md) | [546](/filings/0000920148-26-000139.md) | [579](/filings/0000920148-26-000175.md) | [552](/filings/0000920148-25-000096.md) | [539 d](/filings/0000920148-26-000111.md) | [551](/filings/0000920148-26-000139.md) | [577](/filings/0000920148-26-000175.md) |
| Operating income | $m | [252](/filings/0000920148-24-000118.md) | [(123) d](/filings/0000920148-26-000111.md) | [321](/filings/0000920148-25-000059.md) | [295](/filings/0000920148-25-000081.md) | [254](/filings/0000920148-25-000096.md) | [217 d](/filings/0000920148-26-000111.md) | [326](/filings/0000920148-26-000139.md) | [395](/filings/0000920148-26-000175.md) | [397](/filings/0000920148-25-000096.md) | [268 d](/filings/0000920148-26-000111.md) | [381](/filings/0000920148-26-000139.md) | [452](/filings/0000920148-26-000175.md) |
| Interest expense | $m | [50.3](/filings/0000920148-24-000118.md) | [48.8 d](/filings/0000920148-26-000111.md) | [46.9](/filings/0000920148-25-000059.md) | [47.6](/filings/0000920148-25-000081.md) | [50.4](/filings/0000920148-25-000096.md) | [63.4 d](/filings/0000920148-26-000111.md) | [56.0](/filings/0000920148-26-000139.md) | [57.1](/filings/0000920148-26-000175.md) | [56.0](/filings/0000920148-25-000096.md) | [55.0 d](/filings/0000920148-26-000111.md) | [55.1](/filings/0000920148-26-000139.md) | [61.1](/filings/0000920148-26-000175.md) |
| Income tax | $m | [55.1](/filings/0000920148-24-000118.md) | [19.7 d](/filings/0000920148-26-000111.md) | [69.1](/filings/0000920148-25-000059.md) | [62.1](/filings/0000920148-25-000081.md) | [41.0](/filings/0000920148-25-000096.md) | [40.2 d](/filings/0000920148-26-000111.md) | [62.2](/filings/0000920148-26-000139.md) | [66.4](/filings/0000920148-26-000175.md) | [75.5](/filings/0000920148-25-000096.md) | [25.7 d](/filings/0000920148-26-000111.md) | [41.7](/filings/0000920148-26-000139.md) | [87.3](/filings/0000920148-26-000175.md) |
| Net income | $m | [183](/filings/0000920148-24-000118.md) | [(167) d](/filings/0000920148-26-000111.md) | [228](/filings/0000920148-25-000096.md) | [205](/filings/0000920148-25-000096.md) | [169](/filings/0000920148-25-000096.md) | [143 d](/filings/0000920148-26-000111.md) | [213](/filings/0000920148-26-000175.md) | [238](/filings/0000920148-26-000175.md) | [261](/filings/0000920148-25-000096.md) | [165 d](/filings/0000920148-26-000111.md) | [278](/filings/0000920148-26-000175.md) | [299](/filings/0000920148-26-000175.md) |
| Diluted EPS | $ per share | [2.11](/filings/0000920148-24-000118.md) | not reported | [2.69](/filings/0000920148-25-000059.md) | [2.43](/filings/0000920148-25-000081.md) | [2.00](/filings/0000920148-25-000096.md) | not reported | [2.52](/filings/0000920148-26-000139.md) | [2.84](/filings/0000920148-26-000175.md) | [3.12](/filings/0000920148-25-000096.md) | not reported | [3.35](/filings/0000920148-26-000139.md) | [3.64](/filings/0000920148-26-000175.md) |
| Basic EPS | $ per share | [2.12](/filings/0000920148-24-000118.md) | not reported | [2.71](/filings/0000920148-25-000059.md) | [2.44](/filings/0000920148-25-000081.md) | [2.02](/filings/0000920148-25-000096.md) | not reported | [2.54](/filings/0000920148-26-000139.md) | [2.85](/filings/0000920148-26-000175.md) | [3.14](/filings/0000920148-25-000096.md) | not reported | [3.37](/filings/0000920148-26-000139.md) | [3.66](/filings/0000920148-26-000175.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.7](/filings/0000920148-23-000081.md) | [0.5](/filings/0000920148-26-000111.md) | [0.1](/filings/0000920148-24-000032.md) | [0.3](/filings/0000920148-24-000099.md) | [1.5](/filings/0000920148-24-000118.md) | [1.5](/filings/0000920148-26-000111.md) | [0.4](/filings/0000920148-26-000139.md) | [0.6](/filings/0000920148-26-000175.md) | [0.6](/filings/0000920148-25-000096.md) | [0.5](/filings/0000920148-26-000175.md) | [1.0](/filings/0000920148-26-000139.md) | [0.1](/filings/0000920148-26-000175.md) |
| Current assets | $bn | [4.0](/filings/0000920148-23-000081.md) | [3.8](/filings/0000920148-25-000032.md) | [3.5](/filings/0000920148-24-000032.md) | [3.6](/filings/0000920148-24-000099.md) | [4.9](/filings/0000920148-24-000118.md) | [4.8](/filings/0000920148-26-000111.md) | [3.8](/filings/0000920148-25-000059.md) | [4.1](/filings/0000920148-25-000081.md) | [4.1](/filings/0000920148-25-000096.md) | [4.0](/filings/0000920148-26-000175.md) | [4.6](/filings/0000920148-26-000139.md) | [3.8](/filings/0000920148-26-000175.md) |
| Total assets | $bn | [16.9](/filings/0000920148-23-000081.md) | [16.7](/filings/0000920148-25-000032.md) | [16.5](/filings/0000920148-24-000032.md) | [16.7](/filings/0000920148-24-000099.md) | [18.6](/filings/0000920148-24-000118.md) | [18.4](/filings/0000920148-26-000111.md) | [17.6](/filings/0000920148-25-000059.md) | [18.1](/filings/0000920148-25-000081.md) | [18.3](/filings/0000920148-25-000096.md) | [18.4](/filings/0000920148-26-000175.md) | [19.1](/filings/0000920148-26-000139.md) | [18.5](/filings/0000920148-26-000175.md) |
| Current liabilities | $bn | [2.9](/filings/0000920148-23-000081.md) | [3.2](/filings/0000920148-25-000032.md) | [3.9](/filings/0000920148-24-000032.md) | [4.1](/filings/0000920148-24-000099.md) | [3.4](/filings/0000920148-24-000118.md) | [3.3](/filings/0000920148-26-000111.md) | [2.1](/filings/0000920148-25-000059.md) | [2.7](/filings/0000920148-25-000081.md) | [2.6](/filings/0000920148-25-000096.md) | [2.8](/filings/0000920148-26-000175.md) | [2.6](/filings/0000920148-26-000139.md) | [2.1](/filings/0000920148-26-000175.md) |
| Total liabilities | $bn | [9.0](/filings/0000920148-23-000081.md) | [8.8](/filings/0000920148-25-000032.md) | [8.6](/filings/0000920148-24-000032.md) | [8.7](/filings/0000920148-24-000099.md) | [10.4](/filings/0000920148-24-000118.md) | [10.3](/filings/0000920148-26-000111.md) | [9.3](/filings/0000920148-25-000059.md) | [9.6](/filings/0000920148-25-000081.md) | [9.5](/filings/0000920148-25-000096.md) | [9.8](/filings/0000920148-26-000175.md) | [10.3](/filings/0000920148-26-000139.md) | [9.9](/filings/0000920148-26-000175.md) |
| Long-term debt | $bn | [4.4](/filings/0000920148-23-000081.md) | [4.1](/filings/0000920148-25-000032.md) | [3.0](/filings/0000920148-24-000032.md) | [3.0](/filings/0000920148-24-000099.md) | [5.4](/filings/0000920148-24-000118.md) | [5.3](/filings/0000920148-26-000111.md) | [5.6](/filings/0000920148-25-000059.md) | [5.1](/filings/0000920148-25-000081.md) | [5.1](/filings/0000920148-25-000096.md) | [5.1](/filings/0000920148-26-000175.md) | [5.8](/filings/0000920148-26-000139.md) | [5.9](/filings/0000920148-26-000175.md) |
| Current portion of debt | $bn | not reported | [1.0](/filings/0000920148-25-000032.md) | not reported | not reported | not reported | [1.0](/filings/0000920148-26-000111.md) | not reported | not reported | not reported | [0.5](/filings/0000920148-26-000175.md) | [0.5](/filings/0000920148-26-000139.md) | [0.0](/filings/0000920148-26-000175.md) |
| Shareholders' equity | $bn | [7.9](/filings/0000920148-24-000118.md) | [7.9](/filings/0000920148-26-000111.md) | [8.0](/filings/0000920148-25-000096.md) | [8.0](/filings/0000920148-25-000096.md) | [8.2](/filings/0000920148-25-000096.md) | [8.1](/filings/0000920148-26-000175.md) | [8.3](/filings/0000920148-26-000175.md) | [8.5](/filings/0000920148-26-000175.md) | [8.7](/filings/0000920148-25-000096.md) | [8.6](/filings/0000920148-26-000175.md) | [8.7](/filings/0000920148-26-000175.md) | [8.6](/filings/0000920148-26-000175.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [276 d](/filings/0000920148-24-000118.md) | [580 d](/filings/0000920148-26-000111.md) | [(29.8)](/filings/0000920148-25-000059.md) | [561 d](/filings/0000920148-25-000081.md) | [277 d](/filings/0000920148-25-000096.md) | [777 d](/filings/0000920148-26-000111.md) | [18.5](/filings/0000920148-26-000139.md) | [621 d](/filings/0000920148-26-000175.md) | [387 d](/filings/0000920148-25-000096.md) | [614 d](/filings/0000920148-26-000111.md) | [192](/filings/0000920148-26-000139.md) | [446 d](/filings/0000920148-26-000175.md) |
| Capital expenditure | $m | [105 d](/filings/0000920148-24-000118.md) | [167 d](/filings/0000920148-26-000111.md) | [134](/filings/0000920148-25-000059.md) | [128 d](/filings/0000920148-25-000081.md) | [116 d](/filings/0000920148-25-000096.md) | [112 d](/filings/0000920148-26-000111.md) | [126](/filings/0000920148-26-000139.md) | [77.9 d](/filings/0000920148-26-000175.md) | [107 d](/filings/0000920148-25-000096.md) | [124 d](/filings/0000920148-26-000111.md) | [121](/filings/0000920148-26-000139.md) | [132 d](/filings/0000920148-26-000175.md) |
| Dividends paid | $m | [63.9 d](/filings/0000920148-24-000118.md) | [61.1 d](/filings/0000920148-26-000111.md) | [62.1](/filings/0000920148-25-000059.md) | [60.4 d](/filings/0000920148-25-000081.md) | [60.5 d](/filings/0000920148-25-000096.md) | [60.1 d](/filings/0000920148-26-000111.md) | [61.6](/filings/0000920148-26-000139.md) | [59.9 d](/filings/0000920148-26-000175.md) | [59.9 d](/filings/0000920148-25-000096.md) | [59.3 d](/filings/0000920148-26-000111.md) | [61.2](/filings/0000920148-26-000139.md) | [58.7 d](/filings/0000920148-26-000175.md) |
| Share repurchases | $m | [1,009 d](/filings/0000920148-24-000118.md) | [(9.0) d](/filings/0000920148-26-000111.md) | not reported | not reported | [75.0 d](/filings/0000920148-25-000096.md) | [75.1 d](/filings/0000920148-26-000111.md) | [0.0](/filings/0000920148-26-000139.md) | [200 d](/filings/0000920148-26-000175.md) | [25.0 d](/filings/0000920148-25-000096.md) | [225 d](/filings/0000920148-26-000111.md) | [98.0](/filings/0000920148-26-000139.md) | [354 d](/filings/0000920148-26-000175.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [90.7](/filings/0000920148-23-000081.md) | [89.0](/filings/0000920148-24-000032.md) | [89.0](/filings/0000920148-24-000099.md) | [87.0](/filings/0000920148-24-000118.md) | [84.7](/filings/0000920148-25-000059.md) | [84.3](/filings/0000920148-25-000081.md) | [84.4](/filings/0000920148-25-000096.md) | [84.3](/filings/0000920148-26-000139.md) | [83.9](/filings/0000920148-26-000175.md) | [83.7](/filings/0000920148-25-000096.md) | [82.9](/filings/0000920148-26-000139.md) | [82.0](/filings/0000920148-26-000175.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 81,100,000 at 2026-08-04, from the cover of the [10-Q filed 2026-08-05](/filings/0000920148-26-000175.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.